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Abstract
Since the first reports in the late 1990s connecting elevated circulating levels of C-reactive protein in
patients with end-stage renal disease with an atherogenic, wasted phenotype and poor outcome,
more than 3600 publications related to the subject have appeared on the Medline bibliographic
database. This reflects the exponential interest that this topic has evoked in the field of nephrology,
and the possibility of treating this common uremic complication has been much discussed. Several
small studies have implied that various nutritional and pharmacological treatment strategies have
beneficial effects on surrogate markers of inflammation. However, no randomized controlled trials on
anti-inflammatory treatment have yet been performed to test the hypothesis that persistent low-
grade inflammation contributes to uremic morbidity and mortality.
Introduction and context
As the majority of recent randomized controlled trials
(RCTs) have been unable to demonstrate a beneficial
effect of various interventions aimed at improving out-
come in end-stage renal disease (ESRD) [1], novel
treatment strategies need to be tested in this high-risk
patient group. Among several novel risk factors, inflam-
mation has attracted considerable interest in the last
10 years [2]. Although cytokine production is necessary to
protect against pathogens and promote tissue repair,
excessive release or decreased clearance (or both) can lead
to organ failure and premature death. Detailed reviews on
causes of inflammation in the context of impaired renal
function have recently been published [2,3]. Prospective
studies in hemodialysis, peritoneal dialysis, and renal
transplantation patients show that even a single measure-
ment of inflammatory biomarkers independently predicts
poor outcome [2]. Furthermore, inflammation has been
identified as a strong prognosticator of sudden death in
ESRD patients [4], which indirectly supports a link bet-
ween persistent inflammation and an imbalance between
the sympathetic and parasympathetic nervous system [5].
In 2008, a large genetic study of patients with ischemic
heart disease (and controls) showed that C-reactive
protein (CRP) polymorphisms are not in themselves
associated with an increased risk of ischemic vascular
disease, therefore, available evidence suggests that
although CRP is a strong risk marker, it is not a risk factor
of cardiovascular disease [6]. In fact, among numerous
studies that have shown that inflammatory biomarkers
or cells involved in the inflammatory cascade predict
outcome, interleukin (IL)-6 seems to be the strongest
predictor of cardiovascular morbidity and outcome [7].
Another study showed that by defining specific cytokine
ratios related to the inflammatory and immunologic
states,itseemspossibletofinetunethepredictionofdeath
from cardiovascular and non-cardiovascular causes [8].
Based on the observation that persistent inflamma-
tion may serve as a catalyst and magnify the risk of poor
outcome via mechanisms related to self-enhancement of
the inflammatory cascade and exacerbation of the wasting
and calcification processes [3], it can be argued that the
effects of different interventions should be analyzed
separatelyininflamedand non-inflamed dialysis patients.
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Although inflammatory markers persistently predict
outcome in dialysis patients or following kidney trans-
plantation, few studies have studied the effect of various
anti-inflammatory interventions on outcome [2]. How-
ever, as small studies have shown encouraging results
after examining the levels of inflammatory biomarkers
following intervention with gamma-tocopherol [9], soy
[10], green tea [11], cholecalciferol [12] and sevelamer
[13], the renal community should conduct sufficiently
powered RCTs to prove the concept that treatment of
persistent inflammation may provide benefit in re-
ducing uremic morbidity and mortality. In a recent
RCT involving 2776 hemodialysis patients, the effects
of rosuvastatin versus placebo were compared [14]. No
effect on mortality was observed despite a small reduc-
tion of CRP following statin treatment. However, as the
interaction between CRP and the effect of rosuvastatin
was not checked, we do not know if the effects of statins
on the outcome differ between inflamed and uninflamed
dialysis patients.
No large study has yet tested if anti-cytokine therapy
affects surrogate biomarkers of inflammation, morbid-
ity, and mortality. However, as therapy targeting IL-1b-
mediated inflammation not only reduces inflammation
biomarkers but also holds promise for the treatment of
glycemic control in type 2 diabetic patients [15], it can be
speculated that targeted IL-1 antagonism may also
benefit uremic patients. In a recent pilot study of 10
dialysis patients that were randomly assigned to receive
either the tumour necrosis factor-alpha (TNF-a) antago-
nist etanercept or placebo twice weekly for 44 weeks, no
significant effects on inflammatory biomarkers were
observed [16]. However, as a significant difference in the
time-dependent effects of etanercept on prealbumin was
observed (levels increased by 20% in the etanercept
group and decreased in the placebo group), favorable
effects on nutritional markers may be anticipated. As no
adverse side effects were observed, administration of
TNF-a receptor antagonism seems safe in selected
dialysis patients despite their documented increased
risk of infectious complications. Thus, larger studies are
now needed to test the effects of selective anti-TNF, IL-1,
and IL-6 therapies, respectively, not only on inflamma-
tory and nutritional surrogate markers but also on
morbidity and outcome. No doubt, the major problem
in such a RCT will be to select the patients with persistent
non-infectious uremic inflammation.
Implications for clinical practice
Until adequately powered RCTs have been performed
with anti-inflammatory treatment strategies, no specific
pharmacological treatment recommendations for uremic
inflammation can be advocated. However, clinicians
should be aware of the strong association between
persistent inflammation and outcome before carefully
evaluating (and if possible treating) the multiple
putative causes of persistent inflammation in this patient
group. Although the clinician may minimize some
aggravating factors that promote inflammation in the
context of renal disease, it may not be possible to get rid
of inflammation in a clinical situation. Due to the fact
that causes both unrelated to dialysis (such as inter-
current infectious and inflammatory complications,
peridontitis, and ischemic heart disease) and related
to dialysis (such as bioincompatibility, residual renal
function, infections of vascular access, dialysis hypoten-
sion, impure dialysate, and volume overload) can con-
tribute to uremic inflammation, the clinician needs to
carefully evaluate all chronic kidney disease patients with
signs of inflammation such as elevated CRP levels.
Indeed, a recent study demonstrated lower cardiovascu-
lar mortality in dialysis units in which CRP was regularly
monitored [17].
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